| Outcome Measures: |
Primary: Refill accuracy between the 2 insulin groups, During 4 refill cycles|Change in glycosylated hemoglobin (HbA1c), From baseline to 6 months | Secondary: Occurrence of Hypoglycaemia (asymptomatic and symptomatic hypoglycaemia, severe and serious symptomatic hypoglycaemia, From baseline to 6 months|Occurrence of hyperglycaemia, From baseline to 6 months|Occurrence of diabetic ketoacidosis, From baseline to 6 months|Change in insulin dose, From baseline to 6 months|Antibody assessments (anti-Insulin antibodies), From baseline to 6 months
|
| Locations: |
Investigational Site Number 056-001, Leuven, 3000, Belgium|Investigational Site Number 250-004, Corbeil Essonnes, 91100, France|Investigational Site Number 250-008, Dijon, 21000, France|Investigational Site Number 250-003, Dommartin Les Toul, 54200, France|Investigational Site Number 250-012, Le Mans Cedex 9, 72037, France|Investigational Site Number 250-009, LILLE Cedex, 59037, France|Investigational Site Number 250-007, Marseille, 13385, France|Investigational Site Number 250-001, MONTPELLIER Cedex 5, 34295, France|Investigational Site Number 250-005, Paris, 75014, France|Investigational Site Number 250-010, Pessac Cedex, 33604, France|Investigational Site Number 250-011, ST PRIEST EN JAREZ Cedex, 42277, France|Investigational Site Number 250-002, Strasbourg, 67091, France|Investigational Site Number 250-006, TOULOUSE Cedex 9, 31059, France|Investigational Site Number 528003, Den Haag, 2512VA, Netherlands|Investigational Site Number 528002, Roermond, 6043CV, Netherlands|Investigational Site Number 528001, Zwolle, 8025AB, Netherlands|Investigational Site Number 752-001, Stockholm, Sweden
|
